Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Pacira BioSciences, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-67.2% vs price
Base Case (Median)
-30.7% vs price
Bull Case (75th pct.)
132.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $84.80 | 133.4% | High (40%) |
| PE Comparable | $8.20 | -77.4% | Medium (25%) |
| Graham Number | $11.93 | -67.2% | Medium (40%) |
| EV/EBITDA | $25.18 | -30.7% | Medium (20%) |
| EV/FCF | $84.40 | 132.3% | Medium (20%) |
Based on 5 out of 7 methods, PCRX appears fairly valued at the current price of $36.34. The base case fair value of $25.18 implies 30.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.